# A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer

> **NCT00090701** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Lung Neoplasms

## Interventions

- **DRUG:** AG2037

## Key facts

- **NCT ID:** NCT00090701
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2012-05-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00090701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00090701, "A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00090701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*